Computational Approaches That Predict Metabolic Intermediate Complex Formation with CYP3A4 (+b5)

Some mechanism-based inhibitors cause irreversible inhibition by forming a metabolic intermediate complex (MIC) with cytochrome P450. In the present study, 54 molecules (substrates of CYP3A and amine-containing compounds that are not known substrates of CYP3A) were spectrophotometrically assessed for their propensity to cause MIC formation with recombinant CYP3A4 (+b5). Comparisons of common physicochemical properties showed that mean (±S.D.) mol. wt. of MIC-forming compounds was significantly greater than mean mol. wt. of non-MIC-forming compounds, 472 (±173) versus 307 (±137), respectively. Computational pharmacophores, logistic regression, and recursive partitioning (RP) approaches were applied to predict MIC formation from molecular structure and to generate a quantitative structure activity relationship. A pharmacophore built with SKF-525A (2-diethylaminoethyl 2:2-diphenylvalerate hydrochloride), erythromycin, amprenavir, and norverapamil indicated that four hydrophobic features and a hydrogen bond acceptor were important for these MIC-forming compounds. Two different RP methods using either simple descriptors or 2D augmented atom descriptors indicated that hydro-phobic and hydrogen bond acceptor features were required for MIC formation. Both of these RP methods correctly predicted the MIC formation status with CYP3A4 for 10 of 12 literature molecules in an independent test set. Logistic multiple regression and a third classification tree model predicted 11 of 12 molecules correctly. Both models possessed a hydrogen bond acceptor and represent an approach for predicting CYP3A4 MIC formation that can be improved using more data and molecular descriptors. The preliminary pharmacophores provide structural insights that complement those for CYP3A4 inhibitors and substrates.

[1]  C. Ernest,et al.  Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors , 2005, Journal of Pharmacology and Experimental Therapeutics.

[2]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[3]  S. Dworetzky,et al.  Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition. , 2003, Journal of medicinal chemistry.

[4]  C. Hansch,et al.  Quantitative structure-activity relationships of cytochrome P-450. , 1993, Drug metabolism reviews.

[5]  Mark T. D. Cronin,et al.  Structure-Based Classification of Antibacterial Activity , 2002, J. Chem. Inf. Comput. Sci..

[6]  Sean Ekins,et al.  Generation and validation of rapid computational filters for cyp2d6 and cyp3a4. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[7]  P. Chatterjee,et al.  Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[8]  B. Ring,et al.  Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[9]  Sean Ekins,et al.  Development of Computational Models for Enzymes, Transporters, Channels, and Receptors Relevant to ADME/Tox , 2004 .

[10]  N. Vermeulen,et al.  A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108. , 1996, Chemical research in toxicology.

[11]  S. Hall,et al.  Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[12]  Sean Ekins,et al.  In vitro and pharmacophore insights into CYP3A enzymes. , 2003, Trends in pharmacological sciences.

[13]  L. Pershing,et al.  Cytochrome P-450 metabolic-intermediate complex formation and induction by macrolide antibiotics; a new class of agents. , 1982, Xenobiotica; the fate of foreign compounds in biological systems.

[14]  Chris de Graaf,et al.  Cytochrome p450 in silico: an integrative modeling approach. , 2005, Journal of medicinal chemistry.

[15]  Sean Ekins,et al.  Optimizing Higher Throughput Methods to Assess Drug-Drug Interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 In Vitro Using a Single Point IC50 , 2002, Journal of biomolecular screening.

[16]  Sean Ekins,et al.  Pharmacophore modeling of cytochromes P450. , 2002, Advanced drug delivery reviews.

[17]  H. Yamazaki,et al.  Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[18]  M. Franklin Inhibition of mixed-function oxidations by substrates forming reduced cytochrome P-450 metabolic-intermediate complexes , 1977 .

[19]  S. Stanley Young,et al.  Automated Pharmacophore Identification for Large Chemical Data Sets. , 1999 .

[20]  H. Suzuki,et al.  Studies on the cytochrome P450 (CYP)-mediated metabolic properties of miocamycin: evaluation of the possibility of a metabolic intermediate complex formation with CYP, and identification of the human CYP isoforms. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[21]  S. Ekins,et al.  Pharmacophore and three-dimensional quantitative structure activity relationship methods for modeling cytochrome p450 active sites. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[22]  A. Alex,et al.  Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.

[23]  D. Hawkins,et al.  Analysis of a Large Structure‐Activity Data Set Using Recursive Partitioning , 1997 .

[24]  D. Jones,et al.  Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. , 1999, The Journal of pharmacology and experimental therapeutics.

[25]  T. Sjögren,et al.  Structural basis for ligand promiscuity in cytochrome P450 3A4 , 2006, Proceedings of the National Academy of Sciences.

[26]  A. Alex,et al.  A novel approach to predicting P450 mediated drug metabolism. CYP2D6 catalyzed N-dealkylation reactions and qualitative metabolite predictions using a combined protein and pharmacophore model for CYP2D6. , 1999, Journal of medicinal chemistry.

[27]  P. Watkins,et al.  THE HUMAN CYP3A SUBFAMILY: PRACTICAL CONSIDERATIONS* , 2000, Drug metabolism reviews.

[28]  Xin Chen,et al.  Automated Pharmacophore Identification for Large Chemical Data Sets1 , 1999, J. Chem. Inf. Comput. Sci..

[29]  E. Fuse,et al.  Effects of olopatadine, a new antiallergic agent, on human liver microsomal cytochrome P450 activities. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[30]  S. Grimm,et al.  Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites , 2002, Xenobiotica; the fate of foreign compounds in biological systems.

[31]  R. Silverman Mechanism-based enzyme inactivation : chemistry and enzymology , 1988 .

[32]  R. J. Riley,et al.  Development of a Generalized, Quantitative Physicochemical Model of CYP3A4 Inhibition for Use in Early Drug Discovery , 2001, Pharmaceutical Research.

[33]  S. Ekins,et al.  Present and future in vitro approaches for drug metabolism. , 2000, Journal of pharmacological and toxicological methods.

[34]  S. Ekins,et al.  Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. , 1999, The Journal of pharmacology and experimental therapeutics.

[35]  Osman F. Güner,et al.  Pharmacophore perception, development, and use in drug design , 2000 .

[36]  Sean Ekins,et al.  QUANTITATIVE STRUCTURE-METABOLISM RELATIONSHIP MODELING OF METABOLIC N-DEALKYLATION REACTION RATES , 2004, Drug Metabolism and Disposition.

[37]  S D Hall,et al.  An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[38]  Christophe G. Lambert,et al.  Mixture deconvolution and analysis of Ames mutagenicity data , 2002 .

[39]  David W. Hosmer,et al.  Applied Logistic Regression , 1991 .

[40]  D. Stresser,et al.  Fluorometric screening for metabolism-based drug--drug interactions. , 2000, Journal of pharmacological and toxicological methods.

[41]  Jeffrey P. Jones,et al.  Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[42]  S. O. Kim,et al.  Characterization of the selectivity and mechanism of cytochrome P450 inhibition by dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylenedioxybiphenyl-2,2'-dicarboxylate. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[43]  Xin Chen,et al.  Recursive Partitioning Analysis of a Large Structure-Activity Data Set Using Three-Dimensional Descriptors1 , 1998, J. Chem. Inf. Comput. Sci..